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Background: Alcoholic hepatitis (AH) is a severe form of alcoholic liver disease (ALD) 
associated with significant short-term mortality. Existing treatment therapies are not completely 
effective, highlighting the need to identify molecular drivers in AH. NGAL has recently been 
identified as one of the most overexpressed genes in patients with AH. 
 
Aims: To investigate the role of NGAL as a potential target for therapy in AH using a 
translational approach including human samples and animal models. 
 
Methods: NGAL expression was analyzed in patients with AH, animal models of liver 
inflammation and fibrogenesis, and cell lines of human hepatocytes. Fibrosis- and inflammation-
marker genes were analyzed for expression in hepatic stellate cell (HSC) cell lines treated with 
NGAL. RNA was extracted from all samples and gene expression of cDNA was measured using 
real-time qPCR analysis. 
 
Results: Gene expression of NGAL in patients with AH had a 44-fold increase in comparison to 
several other liver diseases. Animal models of liver inflammation and fibrosis had increased 
NGAL expression. Although cell lines of human hepatocytes exhibited greater NGAL expression 
than HSC cell lines, there was no noticeable increase in NGAL expression with subsequent pro-
inflammatory induction of hepatocyte cell lines. HSC cell lines showed increased expression of 
several markers of fibrosis and inflammation with NGAL treatment.  
5 
 
 
Conclusion: NGAL is overexpressed in patients with AH and in animal models of liver 
inflammation and fibrosis and it exerts fibrogenic and inflammatory effects in hepatic stellate 
cells. Results suggest that NGAL may be a potential target for therapy in AH. Further studies 
should be done to more fully explore the nature of NGAL overexpression in AH.  
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II. INTRODUCTION 
Alcohol-related illness and death has become increasingly prevalent worldwide. ALD 
progression includes steatosis, AH, fibrosis, and cirrhosis.
1
 Steatosis, or fatty liver, develops in 
over 95% of heavy drinkers
1 
and is marked by small- and large-droplet fat beginning in 
perivenular regions.
2
 Persistent alcohol consumption leads to fibrosis in 20-40% of patients with 
steatosis, characterized by excessive accumulation of collagen and other extracellular matrix 
proteins.
1
 In 8-20% of patients who have developed fibrosis, further scar tissue formation 
through cirrhosis can occur as a result of continued alcohol consumption.
1 
 AH is an acute 
inflammatory syndrome
3
 whose features include hepatocyte ballooning and neutrophil-rich 
parenchymal inflammation.
2
 AH ranges in severity from mild forms that resolve with 
conservative management to severe presentations that are associated with mortality as high as 
65%.
3
 Although there are several therapeutic measures currently available to improve survival in 
patients with AH, the overall quality of treatments is lacking.
4
 The use of glucocorticoids, the 
most commonly administered treatment for severe AH, is still controversial and there is a 
significant group of patients who have glucocorticoid-resistant disease.
1
 The development of new 
therapeutic approaches in AH has been difficult due to the fact that available animal models do 
not reproduce all of the key histological features found in humans.
5
 Thus, it is imperative that 
molecular drivers of AH be identified as new targets for therapy. 
 A preliminary transcriptome analysis performed by our lab group indicated that NGAL 
expression had a 44-fold increase in patients with AH when compared to other genes. NGAL is 
an inflammatory protein belonging to the lipocalin superfamily released by activated 
neutrophils.
6
 Lipopolysaccharide (LPS) is a major mediator of neutrophil activation,
7
 indicating 
that the LPS signaling pathway regulates NGAL gene expression. NGAL is considered to be the 
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most promising biomarker of acute kidney injury (AKI) through its release by damaged 
parenchymal cells,
8
 but its role in AH is largely unknown. 
Alcohol intake affects inflammation in the liver through induction by LPS. LPS is a key cell 
wall component of Gram-negative bacteria and it mimics bacterial infection by causing an acute 
inflammatory response.
9
 Kupffer cells are macrophages in the liver that, when exposed to LPS, 
activate and produce pro-inflammatory cytokines.
10
 This study analyzed the association between 
LPS induction and NGAL expression in several animal models and human cell lines.  
Alcohol consumption also presents fibrogenic effects in the liver through several pathways 
that induce HSC activation.
1
 HSCs are located in the perisinusoidal space and account for 5-8% 
of the cells in the liver.
11
 In the absence of liver injury, HSCs are in a quiescent, inactivated state. 
When the liver is damaged due to viral infection or hepatic toxins, HSCs receive signals secreted 
by damaged hepatocytes and immune cells, causing them to activate into myofibroblast-like 
cells.
11
 As the primary extracellular matrix (ECM)-producing cells in the liver, activated HSCs 
generate a temporary scar at the site of injury to protect from further damage.
11
 In chronic liver 
disease, prolonged activation of HSCs causes liver fibrosis. Carbon tetrachloride (CCL4) is a 
well-known toxin that is commonly used to induce hepatic injuries in experimental animal 
models
12
 and in this study was used to model fibrosis in mice. As one of the principal responders 
to damage in the liver, it is thus hypothesized that activated HSCs would increase expression of 
NGAL. 
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III. METHODS 
AH Patient Samples 
Patients admitted to the Liver Unit, Hospital Clínic of Barcelona from 2007 to 2010 with 
clinical, analytical and histological features of AH were prospectively included in our 
sample.
13,14,15
 Inclusion criteria have been defined in a previous study.
16
 All patients had a 
histological diagnosis of AH (n = 34) and patients with hepatocellular carcinoma or any other 
potential liver disease were excluded from the study. Liver biopsies were obtained using a 
transjugular approach. For controls, fragments of normal liver tissue (n = 6) were obtained from 
optimal cadaveric liver donors (n = 3) or by resection of liver metastases (n = 3) as described in 
detail in a previous study.
16
 Liver specimens were analyzed by a pathologist. Part of the biopsy 
was submerged into a RNA stabilization solution (RNAlater, Ambion, Austin, Texas, USA). All 
patients gave informed consent and the protocol was approved by the Ethics Committee of the 
Hospital Clínic of Barcelona.  
Mouse Models 
In the fibrosis model, hepatic fibrosis was induced in male BALB/c mice (Bar Harbor, ME, 
USA) following administration of carbon tetrachloride (CCL4) (Sigma-Aldrich, St Louis, MO, 
USA) injected intraperitoneally at a dose of 0.5 mL/kg, 12.5%  diluted in corn oil, once a week 
for four weeks. Control mice were given corn oil at the same dose. Mice were sacrificed 48 
hours after administration of the final injection. 
In the fibrosis-plus-alcohol model, hepatic fibrosis was induced in male C57BL/6J mice (Bar 
Harbor, ME, USA) following the administration of CCL4 (Sigma-Aldrich) injected 
intraperitoneally at a dose of 0.5 mL/kg, 12.5% diluted in olive oil, once a week for six weeks. 
Both control groups were given olive oil at the same dose. Following a two day recovery period, 
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a daily gavage of ethanol in the amount of 4g/kg was administered for six days to the fibrosis-
plus-ethanol group and the ethanol-only control group. The other control group did not receive 
the ethanol gavage.  Mice were sacrificed following completion of the six day gavage treatment. 
In the endotoxin-induced inflammation model, LPS (Sigma-Aldrich) was administered to male 
BALB/c mice via an intraperitoneal injection in the amount of 10 mg/kg four hours before 
sacrifice. At the time of sacrifice, mice were ten weeks old. Control mice were not given the LPS 
injection. 
Liver and blood samples were collected. Each group included at least three mice. Mice were kept 
on a 12-hour light/dark cycle and housed in temperature- and humidity-controlled rooms. All 
experimental procedures were reviewed and approved by the University of North Carolina at 
Chapel Hill Institutional Animal Care and Use Committee. 
Rat Models 
Liver slices were prepared using Sprague–Dawley rat pups from dams (Charles River, Raleigh, 
NC). Briefly, livers were dissected from five-day-old neonates in Gey’s buffer and sectioned at 
375 μm with a McILwain tissue chopper. Slices were transferred to a 30-mm diameter membrane 
tissue insert (Millicell-CM; Millipore Corp., Bedford, MA) with six slices per membrane. These 
were then placed in six-well plates, and cultured in 1.2 mL of DMEM medium (Gibco, Grand 
Island, NY) containing 10% fetal bovine serum (FBS) (Sigma-Aldrich) + 2 mM L-glutamine. 
Cultures were maintained in a humidified 5% CO2 incubator at 36.5°C. Liver slices were 
cultured nine days in vitro (DIV) before any treatment. All slices were then treated with LPS (0-
50 ng/ml) (Sigma-Aldrich) for 24 hours. At the end of experiment, the slices were removed for 
RT-PCR analysis. All protocols were approved by the Institutional Animal Care Use Committee 
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and were in accordance with National Institute of Health regulations for the care and use of 
animals in research.   
Cell Cultures 
Cells from HepG2 (Sigma-Aldrich), a human hepatocyte cell line,
17
 were serum-starved for 24 
hours before incubation with LPS 1µg/mL (Sigma-Aldrich) for 20 hours.  
Cells from LX-2 (Scott L. Friedman, Mount Sinai Hospital, New York, NY), a human HSC cell 
line,
18
 were serum-starved for 24 hours before incubation with NGAL 100 ng/mL (Novus 
Biologicals, Littleton, CO) for 20 hours.  
FBS 20%/mL (Sigma-Aldrich) was used as a control for HepG2 and LX-2 cells.  
RNA Isolation and qPCR Analysis 
RNA was isolated from liver tissues, animal models, and human cells using Trizol (Invitrogen, 
Carlsbad, CA, USA), following the manufacturer’s protocol. A high-capacity complementary 
DNA (cDNA) reverse-transcription kit (Applied Biosystems, Foster City, CA, USA) was used to 
retro-transcribe 2,000 ng of RNA. cDNA was then amplified using Taqman Technology 
(Applied Biosystems), with a final PCR volume of 10 µL using a StepOnePlus
TM
 Real-Time 
PCR System (Applied Biosystems). Various assay-on-demand probes and primers (Applied 
Biosystems) were used. For all samples, primer-probe pairs for NGAL were utilized. 
Additionally, MMP2, ACTA2, ICAM1, and MCP1 were used for LX-2 samples. Results were 
normalized to 18s rRNA expression for mouse and human samples, and 45s rRNA expression 
for rat samples. Gene expression was calculated based on the ΔΔCt method. Results are 
expressed as 2
-ΔΔCt
 or as the fold increase compared with the mean expression quantified on 
normal livers. 
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Statistical Analysis 
Results of quantitative variables are expressed as the mean plus standard error unless otherwise 
specified. Differences between groups were analyzed using non-parametric tests (Mann-Whitney 
U test) for continuous variables. Statistical analysis was performed using SPSS version 22 for 
Mac (SPSS Inc., Chicago, IL, USA). 
 
IV. RESULTS 
NGAL Overexpression in Patients with AH 
To confirm preliminary analyses done by our lab group that indicated NGAL was one of the 
most up-regulated genes in patients with AH, we analyzed hepatic NGAL expression in a cohort 
of patients with AH using real-time qPCR analysis. Samples were obtained using a transjugular 
biopsy. Our results confirmed significant NGAL overexpression in patients with AH compared 
to controls and patients with several other liver diseases. Patients with AH had a 44-fold increase 
in expression when compared to these groups (Figure 1).  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Hepatic NGAL gene expression in patients with several liver diseases. (*p<0.05 
compared to all other groups) 
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NGAL Overexpression in Animal Models of Fibrosis 
Although there are no fully-developed animal models that precisely characterize the pathology 
seen in patients with AH,
5
 we used CCL4-induced hepatic fibrosis in mice along with an alcohol 
model to assess NGAL expression. NGAL expression was significantly up-regulated with CCL4 
induction in the fibrosis model when compared to controls that were only given corn oil (Figure 
2A). Similarly, expression of NGAL was significantly greater in fibrosis-plus-alcohol and 
alcohol-only mice, which both received a daily gavage of ethanol for six days, in comparison to 
controls (Figure 2B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. NGAL gene expression in animal models of fibrosis. (A) Hepatic NGAL expression in 
mice treated with CCL4 (*p<0.05 compared to oil control). (B) Hepatic NGAL expression in 
mice treated with ethanol and CCL4 (*p<0.05 compared to control). 
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NGAL Overexpression in Animal Models of Inflammation 
Liver inflammation is also a hallmark of AH.
19
 LPS induction was analyzed for NGAL 
expression in mouse and rat samples. NGAL expression was significantly greater in LPS-
induced mice than in controls (Figure 3A). These results were confirmed in the liver slices of rats 
induced with LPS (Figure 3B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. NGAL gene expression in animal models of inflammation. (A). Hepatic NGAL 
expression in mice treated with LPS. (B) Hepatic NGAL expression in liver slices of rats treated 
with LPS. (*p<0.05 compared to controls) 
 
The Role of Hepatocytes in NGAL Expression and Inflammation 
Because hepatocytes are primarily responsible for regeneration of the liver following 
inflammation-induced injury,
20
 the hepatocyte cell line HepG2 was analyzed for NGAL 
expression. NGAL expression was significantly up-regulated in HepG2 cells when compared to 
expression in LX-2 cells, which are from hepatic stellate cells (Figure 4A). However, when 
HepG2 cells were subsequently induced with LPS, there was no longer an observable association 
with NGAL expression in comparison to controls (Figure 4B).  
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Figure 4. NGAL gene expression in HepG2 cells. (A) NGAL expression in HepG2 and LX-2 
cells (*p<0.05 compared to LX-2). (B) NGAL expression in LPS-induced HepG2 cells. 
 
 
Expression of Fibrosis and Inflammation Markers in LX-2 Cells 
As major responders to liver injury, HSCs play a central role in mediating fibrosis and 
inflammation.
11
 Accordingly, we investigated the expression of several pro-fibrotic and pro-
inflammatory markers in LX-2 cells treated with NGAL to assess NGAL’s role in the regulation 
of these genes. MMP2 and ACTA2, genes that are markers of liver fibrosis, had significantly 
greater expression in LX-2 cells treated with NGAL (Figure 5A). For the markers of 
inflammation, MCP1 expression exhibited similarly significant up-regulation with NGAL 
treatment, while ICAM1 was not found to be significantly associated with NGAL treatment in 
LX-2 cells (Figure 5B).  
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Figure 5. Gene expression of fibrosis and inflammation markers in LX-2 cells. (A) Expression 
of MMP2 and ACTA2 (respectively) in LX-2 cells treated with NGAL (*p<0.05 compared to 
controls). (B) Expression of ICAM1 and MCP1 (respectively) in LX-2 cells treated with NGAL 
(*p<0.05 compared to control). 
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V. DISCUSSION 
 
AH is a severe form of ALD characterized by hepatic fibrosis and inflammation, along with 
overall damage to the liver.
3
 Because existing treatments have not significantly improved 
mortality rates in patients with AH over the past few decades,
1
 it is essential that new, effective 
targets for therapy be identified. In the present study, we investigated the role of NGAL in 
patients with AH, animal models of liver fibrosis and inflammation, and human liver cell lines in 
order to determine whether NGAL may be a novel target for therapy. NGAL overexpression was 
confirmed in patients with AH. Furthermore, NGAL expression was up-regulated in animal 
models of both fibrosis and inflammation, indicating that NGAL may play a role in regulating 
the development of these injuries with respect to the liver. Increased expression of several 
markers of fibrosis and inflammation in LX-2 cells treated with NGAL suggests that HSCs may 
play a role in NGAL’s regulation. Because there was no observed association between induction 
of HepG2 cells with LPS and NGAL expression, it is possible that hepatocytes are not involved 
in the regulation of NGAL during the post-injury phase. 
Several limitations were present in our study. Because alcohol metabolism in rodents differs 
from humans and rodents are averse to the consumption of alcohol, accurate animal models 
reflecting the disease seen in human patients have not been fully developed.
5
 As a result, the 
models used in our study (consisting of CCL4, ethanol, and LPS) likely do not represent AH 
exclusively, but rather ALD in general. Furthermore, due to time and resource constraints, we 
were not able to extend our analyses to human primary cells which would have provided a more 
precise overview of NGAL’s role in AH.  
Future studies may analyze NGAL expression in LPS-induced primary hepatocytes from 
patients with AH in order to fully understand the role that these cells play in NGAL’s regulation. 
17 
 
Primary HSCs treated with NGAL should also be analyzed for other markers of fibrosis and 
inflammation in order to expand our results on NGAL’s role in the regulation of these genes 
during liver injury. Several other targets for treatment of AH have been studied as well. Namely, 
many studies have identified T cells as playing an important future role in AH treatment due to 
their function in the recruitment of neutrophils and the perpetuation of inflammation,
21
 
suggesting that NGAL’s role in association with T cells may also be of forthcoming interest. 
 
VI. CONCLUSION 
NGAL overexpression in patients with AH was confirmed in this study, as well as similar NGAL 
up-regulation seen in human HSC cell lines and animal models of fibrosis and inflammation. 
Thus, we suggest that expression of the gene is likely not linked with hepatocytes, but is 
regulated through HSCs.    
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